Mobilized Leukopaks®, G-CSF + Plerixafor, Fresh
Human mobilized peripheral blood Leukopaks provide a rich source of hematopoietic stem cells as compared to traditional Leukopaks. This allows researchers greater reproducibility of experiments from a single donor (minimize donor-to-donor variation), increase in scalability of experiments from a single product, and a decrease in same cell variability by obtaining high yields of specific cell types.
Mobilized Leukopaks are collected from healthy IRB consented donors that are injected with a combination of 10µg/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) and 240µg/kg of Plerixafor the day before collection, which stimulates the bone marrow to produce hematopoietic stem cells and mobilizes them into the bloodstream, prior to first day of collection. Mobilized mononuclear cells are collected by a trained technician using the Spectra Optia® Apheresis System one and two days post injection. After collection, mobilized Leukopaks are checked by flow analysis to verify the percentage of granulocytes, mononuclear cells, CD34+ cells, and cell viability.
• 2x10e10 TNCs/1 bag
• Enriched PBMCs
• Enriched CD34+ cells
• Low hematocrit
• Low granulocytes
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
We work closely with our customers to provide them with the product they need. For a custom order, please call and speak to one of our sales specialists at 530-303-3828.
|Cell and Tissue Source||Peripheral Blood|
|Cell Type||Mononuclear Cells|
|Donor Attributes||HIV-, HepB-, HepC-|
|Viability||≥90% by Flow Cytometry|
|Size||20 billion TNCs/bag|
|Injections||10μg/kg/day of G-CSF & 240μg/kg Plerixafor the day before collection|